시장보고서
상품코드
1844151

전동 수술기구 시장 : 제품 유형, 전원, 시술 유형, 용도, 최종사용자, 유통 채널별 - 세계 예측(2025-2032년)

Powered Surgical Instruments Market by Product Type, Power Source, Procedure Type, Application, End-User, Distribution Channel - Global Forecast 2025-2032

발행일: | 리서치사: 360iResearch | 페이지 정보: 영문 192 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

전동 수술기구 시장은 2032년까지 CAGR 8.03%로 66억 달러로 성장할 것으로 예측됩니다.

주요 시장 통계
기준 연도 2024년 35억 5,000만 달러
추정 연도 2025년 38억 4,000만 달러
예측 연도 2032 66억 달러
CAGR(%) 8.03%

전동 수술기구 부문의 전략적 방향, 의사결정권자를 위한 임상적 추진력, 공급망 강인성, 경쟁적 필수 요소 강조

전동 수술기기를 둘러싼 환경은 지속적인 기술 발전, 공급 역학 변화, 진화하는 임상 관행으로 인해 제조업체, 의료 서비스 제공자 및 투자자들에게 새로운 전략적 요구사항이 발생하고 있습니다. 이 소개에서는 산업을 재구성하는 수렴적인 힘을 추출하고, 경쟁 우위가 어디에서 생겨나고 있는지, 그리고 다음 계획 기간의 리더십을 결정하는 의사결정의 노드를 밝힙니다.

임상의들은 최소침습 수술과 로봇 보조 수술에 대응하는 정확성, 워크플로우 효율성, 통합된 디지털 기능을 점점 더 많이 요구하고 있습니다. 동시에 의료 서비스 제공자는 장비의 신뢰성, 유지보수성, 애프터마켓 지원을 중시하여 조달 및 총 의료 비용을 최적화하고 있습니다. 부품 조달, 단일 원산지 의존, 법규 준수 등은 모두 시장 출시 시간과 제품 수명주기의 경제성에 영향을 미칩니다.

이러한 역학관계를 종합해 볼 때, 이해관계자들은 혁신에 대한 투자와 현실적인 회복탄력성 대책 사이에서 균형을 맞춰야 합니다. 임상적 증거를 입증하고, 서비스 모델을 간소화하고, 규제와 무역의 복잡성을 극복할 수 있는 기업이 가장 강력한 성장 경로를 찾을 수 있을 것으로 보입니다. 이 요약은 구조적 변화, 관세의 영향, 세분화 인사이트, 지역적 뉘앙스, 경쟁 포지셔닝, 그리고 업계의 시그널을 확실한 전략적 움직임으로 전환하기 위한 권장 행동에 대해 더 깊이 있게 검토할 수 있는 토대를 마련합니다.

기술 통합, 공급망 다각화, 임상적 선호도의 진화가 제품 전략과 상품화 역학을 재구성하는 방법

전동 수술기구 분야는 제품 개발, 상품화, 임상 채택 패턴을 재정의하는 변혁적 변화를 겪고 있습니다. 기술의 발전은 핸드피스와 파워 모듈에 디지털 피드백, 텔레메트리, 인체공학의 통합을 가속화하여 임상의가 더 높은 정확도와 시술 시간 단축을 달성할 수 있게 해주고 있습니다. 이러한 기술 보급은 특수한 기기의 설치 공간과 첨단 플랫폼과의 호환성을 필요로 하는 최소침습적 접근법이나 로봇 보조 접근법에 대한 임상적 선호도가 높아지는 것과 병행하여 이루어지고 있습니다.

공급망 아키텍처는 비용 중심의 모델에서 지리적 분산과 중요 부품의 이중 조달을 중시하는 모델로 전환되고 있습니다. 그 결과, 제조업체들은 공급업체와의 관계를 재평가하고, 근해 능력에 투자하고, 혼란에 대한 노출을 줄이기 위해 재고 버퍼를 구축하고 있습니다. 규제 환경도 마찬가지로 엄격해져 제조 공정 관리, 추적성, 시판 후 조사에 대한 감시가 강화되고 있어 제조업체들은 품질 시스템과 디지털 문서에 대한 투자를 늘리고 있습니다.

상업적으로, 서비스 모델은 거래적 판매에서 장비에 유지보수, 교육, 성과 기반 지표를 번들로 제공하는 라이프사이클 파트너십으로 전환되고 있습니다. 이러한 변화의 배경에는 예측 가능한 운영 성능과 다운타임 감소에 대한 의료 서비스 제공자의 요구가 있습니다. 이러한 변화의 흐름은 고립된 것이 아니라 서로 영향을 주고받으며 새로운 진입 기회를 창출하고, 규모에 의존하는 사업자 간 통합을 촉진하며, 사업자 네트워크 전체에서 제품 증거와 가치 입증의 기준을 높이고 있습니다.

2025년까지의 관세 조정이 어떻게 조달 전략, 양륙 비용 및 전체 계측기 가치사슬의 운영 탄력성을 재구성했는지를 평가합니다.

2025년까지 시행된 관세 조정 및 무역 정책 조치의 누적 효과는 수술용 전기 장비 생태계 내 공급업체의 경제성, 조달 결정 및 가격 전략에 중대한 영향을 미쳤습니다. 관세 변경으로 인해 특정 수입 부품 및 완성된 기기의 상륙 비용이 상승함에 따라 제조업체는 비용 구조를 재평가하고 마진과 경쟁력을 유지하기 위해 전략적 조정을 해야 했습니다.

이에 대응하기 위해 많은 제조업체들이 공급업체 다변화와 현지화를 가속화하고, 관세의 영향을 줄이고, 물류 체인을 단축했습니다. 이러한 조치에는 관세 우대 지역의 대체 공급업체 인증, 주요 제조 공정의 내재화, 지역별로 조립할 수 있는 제품 모듈화 강화 등이 포함됩니다. 일부 제조업체는 관세의 영향을 받는 원재료를 기능적으로 동등하고 수입 관세가 낮은 원재료 및 부품으로 대체하기 위해 표적 재설계를 실시했습니다.

공급업체와 유통업체들은 리드타임의 변동성이 커지고 통관 절차가 복잡해짐에 따라 조달 일정의 압박을 받고 있습니다. 이를 해결하기 위해 조달팀은 공급업체와의 협력 체계를 강화하고, 롤링 인벤토리 방식을 채택하고, 관세 통과 조항과 우발적 상황에 대한 수당을 포함하도록 계약 조건을 재협상했습니다. 또한, 분류 관련 분쟁이나 원산지 결정에 법률 및 세관 전문 지식이 필요한 경우, 규제 준수 비용도 증가했습니다. 전반적으로 관세는 가치사슬 전반의 업무 전환을 촉진하고, 탄력성 중심의 조달, 공급업체 투명성 향상, 총 상륙 비용과 서비스 약속을 더 잘 반영하는 가격 책정 모델로의 전환을 가속화했습니다.

제품 종류, 전원, 시술 수요, 임상 용도, 최종사용자 프로필, 유통 채널을 전략적 우선순위에 따른 상세한 세분화 분석

세분화된 세분화 렌즈를 통해 경쟁 압력과 임상 수요가 집중되는 곳과 전략적 투자를 통해 불균형적인 수익을 얻을 수 있는 곳을 명확히 할 수 있습니다. 제품 유형별로는 수술용 드릴, 수술용 리머, 수술용 톱이 있으며, 수술용 드릴은 유선 드릴과 무선 드릴로, 수술용 리머는 표준 리머와 나사산 리머로, 수술용 톱은 진동 톱과 왕복 톱으로 구분됩니다. 이러한 제품 수준의 구분은 병원 및 외래 수술 센터의 설계 우선순위, 서비스 요구 사항 및 호환성에 대한 기대에 도움이 됩니다.

목차

제1장 서문

제2장 조사 방법

제3장 주요 요약

제4장 시장 개요

제5장 시장 인사이트

제6장 미국 관세의 누적 영향 2025

제7장 AI의 누적 영향 2025

제8장 전동 수술기구 시장 : 제품 유형별

  • 외과용 드릴
    • 코드식 드릴
    • 무선 드릴
  • 외과용 리머
    • 표준 리머
    • 나사산 리머
  • 외과용 톱
    • 진동톱
    • 왕복톱

제9장 전동 수술기구 시장 : 전원별

  • 전기
  • 공기압

제10장 전동 수술기구 시장 : 시술 종류별

  • 최소침습
    • 복강경
    • 로봇 지원
  • 개복 수술

제11장 전동 수술기구 시장 : 용도별

  • 치과 수술
    • 치내요법
    • 임플란트학
  • 이비인후과
    • 귀 수술
    • 부비동 수술
  • 악안면 외과
  • 신경외과
    • 두개 외과
    • 척추 수술
  • 정형외과
    • 골절 고정
    • 관절 치환술
    • 척추 수술

제12장 전동 수술기구 시장 : 최종사용자별

  • 외래 수술 센터
  • 병원
    • 사립 병원
    • 공립 병원
  • 전문 클리닉

제13장 전동 수술기구 시장 : 유통 채널별

  • 직접 판매
    • 온라인 다이렉트
    • 영업부대
  • 판매대리점
    • 전국 판매대리점
    • 지역 판매대리점
  • 온라인 채널

제14장 전동 수술기구 시장 : 지역별

  • 아메리카
    • 북미
    • 라틴아메리카
  • 유럽, 중동 및 아프리카
    • 유럽
    • 중동
    • 아프리카
  • 아시아태평양

제15장 전동 수술기구 시장 : 그룹별

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

제16장 전동 수술기구 시장 : 국가별

  • 미국
  • 캐나다
  • 멕시코
  • 브라질
  • 영국
  • 독일
  • 프랑스
  • 러시아
  • 이탈리아
  • 스페인
  • 중국
  • 인도
  • 일본
  • 호주
  • 한국

제17장 경쟁 구도

  • 시장 점유율 분석, 2024
  • FPNV 포지셔닝 매트릭스, 2024
  • 경쟁 분석
    • Stryker Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Zimmer Biomet Holdings, Inc.
    • Smith & Nephew plc
    • B. Braun Melsungen AG
    • ConMed Corporation
    • Olympus Corporation
    • Integra LifeSciences Holdings Corporation
    • MicroAire Surgical Instruments LLC
KSM 25.10.23

The Powered Surgical Instruments Market is projected to grow by USD 6.60 billion at a CAGR of 8.03% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 3.55 billion
Estimated Year [2025] USD 3.84 billion
Forecast Year [2032] USD 6.60 billion
CAGR (%) 8.03%

A strategic orientation to the powered surgical instruments sector highlighting clinical drivers, supply chain resilience, and competitive imperatives for decision makers

The powered surgical instruments landscape is experiencing a period of sustained technological advancement, shifting supply dynamics, and evolving clinical practices that together define a new strategic imperative for manufacturers, providers, and investors. This introduction distills the convergent forces reshaping the industry, clarifies where competitive advantage is emerging, and highlights the decision nodes that will determine leadership over the next planning horizon.

Clinicians are increasingly demanding precision, workflow efficiency, and integrated digital capabilities that align with minimally invasive and robotic-assisted procedures. Concurrently, providers are optimizing procurement and total cost of care, which places a premium on device reliability, serviceability, and aftermarket support. Supply chains remain a central operational concern: component sourcing, single-origin dependencies, and regulatory compliance all influence time-to-market and product lifecycle economics.

Taken together, these dynamics require stakeholders to balance investment in innovation with pragmatic resilience measures. Firms that can demonstrate clinical evidence, streamline service models, and navigate regulatory and trade complexities will find the strongest runway for growth. This summary sets the stage for a deeper examination of structural shifts, tariff impacts, segmentation insights, regional nuances, competitive positioning, and recommended actions to translate industry signals into high-confidence strategic moves.

How technological integration, supply chain diversification, and evolving clinical preferences are jointly reshaping product strategies and commercialization dynamics

The powered surgical instruments sector is undergoing transformative shifts that are redefining product development, commercialization, and clinical adoption patterns. Technological progress is accelerating the integration of digital feedback, telemetry, and ergonomics into handpieces and power modules, enabling clinicians to achieve greater precision and shorter procedure times. This technological diffusion is occurring alongside increasing clinical preference for minimally invasive and robotic-assisted approaches, which demand specialized instrument footprints and compatibility with advanced platforms.

Supply chain architecture has migrated from a cost-centric model to one that prizes geographic diversification and dual-sourcing for critical components. As a result, manufacturers are reevaluating supplier relationships, investing in nearshore capabilities, and building inventory buffers to reduce exposure to disruptions. Regulatory environments have likewise tightened, with greater scrutiny on manufacturing process controls, traceability, and post-market surveillance, prompting manufacturers to invest in quality systems and digital documentation.

Commercially, service models are shifting from transactional sales toward lifecycle partnerships that bundle instruments with maintenance, training, and outcome-based metrics. This change is driven by provider appetite for predictable operational performance and reduced downtime. Taken together, these transformative shifts are not isolated; they interact to create new entrants' opportunities, force consolidation among scale-dependent players, and raise the bar for product evidence and value demonstration across provider networks.

Assessment of how tariff adjustments through 2025 have reshaped sourcing strategies, landed costs, and operational resilience across the instruments value chain

The cumulative effects of tariff adjustments and trade policy actions implemented through 2025 have materially influenced supplier economics, sourcing decisions, and pricing strategies within the powered surgical instruments ecosystem. Tariff changes have increased landed costs for certain imported components and finished instruments, prompting manufacturers to reassess cost structures and make strategic adjustments to preserve margins and competitiveness.

In response, many manufacturers accelerated supplier diversification and localization efforts to mitigate duty exposure and shorten logistics chains. These measures included qualifying alternative suppliers in tariff-favored jurisdictions, bringing critical manufacturing steps in-house, and enhancing product modularity to allow for regionalized assembly. Some manufacturers implemented targeted redesigns to substitute tariff-affected inputs with functionally equivalent materials or components that carry lower import duties.

Providers and distributors experienced compressed procurement timelines as lead-time variability increased and customs processes became more complex. To manage this, procurement teams intensified collaboration with suppliers, adopted rolling inventory approaches, and renegotiated contract terms to include tariff pass-through clauses and contingency allowances. Regulatory compliance costs also rose where classification disputes or origin determinations required legal and customs expertise. Overall, tariffs catalyzed operational shifts across the value chain, accelerating a move toward resilience-oriented sourcing, greater supplier transparency, and pricing models that better reflect total landed cost and service commitments.

Detailed segmentation analysis linking product variants, power sources, procedural demands, clinical applications, end-user profiles, and distribution channels to strategic priorities

A granular segmentation lens clarifies where competitive pressure and clinical demand will concentrate and where strategic investments will unlock disproportionate returns. Based on product type, the category includes Surgical Drill, Surgical Reamer, and Surgical Saw, with further distinctions such that the Surgical Drill subdivides into Corded Drill and Cordless Drill, the Surgical Reamer separates into Standard Reamer and Threaded Reamer, and the Surgical Saw differentiates into Oscillating Saw and Reciprocating Saw; these product-level distinctions inform design priorities, service requirements, and compatibility expectations for hospitals and ambulatory centers.

Based on power source, instruments fall into Electric and Pneumatic classes, each carrying different maintenance profiles, energy requirements, and facility compatibility considerations that influence purchasing decisions. Based on procedure type, the clinical use cases segment into Minimally Invasive and Open Surgery, where Minimally Invasive further segments into Laparoscopic and Robotic Assisted approaches; this procedural taxonomy drives demand for specialized geometries, lower-profile drives, and integration with robotic platforms or endoscopic toolsets.

Based on application, the instrument set is applied across Dental Surgery, ENT, Maxillofacial Surgery, Neurosurgery, and Orthopedic Surgery, with sub-applications such that Dental Surgery includes Endodontics and Implantology, ENT covers Ear Surgery and Sinus Surgery, Neurosurgery comprises Cranial Surgery and Spinal Surgery, and Orthopedic Surgery addresses Fracture Fixation, Joint Replacement, and Spine Surgery; these clinical applications define sterility protocols, component wear profiles, and the evidence base required to support clinical adoption. Based on end-user, procurement pathways and service expectations differ among Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, noting that Hospitals further differentiate into Private Hospitals and Public Hospitals with distinct purchasing cycles, reimbursement pressures, and capital approval processes. Based on distribution channel, sales and post-sale engagement occur through Direct Sales, Distributors, and Online Channels, where Direct Sales can operate via Online Direct platforms or Sales Force engagements, and Distributors can be National Distributors or Regional Distributors; channel dynamics influence inventory strategies, training delivery, and commercial margins.

Strategic implications emerge from this segmentation: cordless and modular product architectures will appeal to minimally invasive and ambulatory settings, electric power sources will gain traction where integration and digital monitoring are prioritized, and application-specific design will command premium positioning when supported by clinical evidence and service bundles. End-user segmentation underscores the need for tailored commercial approaches, with private hospitals and specialty clinics often receptive to premium solutions that demonstrate operational efficiencies, while public hospitals prioritize total cost and long-term service stability. Distribution choices, finally, influence market reach and scalability, with direct sales enabling deep clinical partnerships and distributor networks offering breadth and localized logistics support.

Comparative regional dynamics and strategic implications across Americas, Europe Middle East & Africa, and Asia-Pacific for product adoption and commercial models

Regional dynamics shape procurement behavior, regulatory expectations, and technology adoption timelines in ways that are consequential for product design and go-to-market planning. In the Americas region, health systems exhibit heterogeneity between private and public providers, strong emphasis on clinical outcome metrics, and significant investment in minimally invasive and robotic-assisted capabilities; procurement cycles in the Americas often favor proven clinical evidence and predictable service performance, and manufacturers that can demonstrate interoperability and robust post-sale support gain a competitive edge.

In Europe, Middle East & Africa, regulatory alignment and reimbursement complexity vary across national boundaries, influencing adoption rates and procurement models. Providers in this region balance cost containment with sophisticated clinical needs, particularly in urban tertiary centers where complex specialties such as neurosurgery and orthopedics require advanced instrument ecosystems. Commercial success in this region depends on regulatory agility, local distribution partnerships, and the ability to support multilingual training and service programs.

In the Asia-Pacific region, demand drivers include growing surgical volumes, rapid expansion of ambulatory care infrastructure, and a strong emphasis on cost-effective innovation. Local manufacturing and regional supply hubs are increasingly important as governments and providers seek to reduce import dependency and improve supply security. Manufacturers that combine competitive pricing, local regulatory strategy, and scalable service models will find expanded opportunities across diverse care settings, particularly where minimally invasive techniques and dental and orthopedic procedures are on the rise.

Competitive landscape analysis revealing the interplay of clinical evidence, aftermarket service excellence, strategic partnerships, and selective vertical integration

Competitive dynamics within the powered surgical instruments arena reveal a blend of legacy incumbents, specialized device innovators, and agile contract manufacturers, creating a multi-tiered ecosystem where differentiation is achieved through clinical evidence, service excellence, and manufacturing efficiency. Leading firms increasingly prioritize integrated solutions that bundle instruments with training, predictive maintenance, and digital analytics to demonstrate improved procedural outcomes and lower total cost of ownership for providers.

Partnerships and strategic alliances have become prevalent as companies seek to combine mechanical expertise with software, sensor technologies, and platform compatibility. Outsourced manufacturing and component specialization persist as important cost and speed levers, but recent strategic moves show a trend toward selective vertical integration for critical components to safeguard quality and mitigate tariff or supply disruptions. Intellectual property portfolios and regulatory track records are decisive factors when providers evaluate long-term suppliers, particularly in high-stakes specialties such as neurosurgery and orthopedic joint replacement.

Service networks and aftermarket capabilities distinguish the most resilient competitors, with rapid-response maintenance, instrument refurbishment programs, and clinician training services enhancing loyalty and reducing lifecycle costs for customers. Firms that can balance scale, evidence generation, and nimble product development will secure preferential access to hospital systems and specialty clinics seeking reliable, clinically proven instrument sets aligned to evolving procedural paradigms.

Actionable strategic roadmap for leadership focused on product modularity, resilient sourcing, enhanced service models, and targeted regional commercialization

Industry leaders should adopt a pragmatic yet forward-looking set of actions to convert emerging trends into durable competitive advantage. First, prioritize modular product architectures that simplify regional assembly and allow rapid substitution of tariff-sensitive components to manage cost volatility without sacrificing clinical performance. Investing in interchangeable drive systems and standardized interfaces will reduce complexity for providers and accelerate certification pathways across geographies.

Second, strengthen service offerings by integrating preventive maintenance, remote diagnostics, and clinician training into commercial contracts to increase revenue predictability and deepen customer relationships. These capabilities are particularly valuable for ambulatory centers and specialty clinics that require high instrument uptime with constrained technical staff. Third, diversify supplier networks and qualify secondary sources for critical components to reduce single-source risk and improve responsiveness to trade policy shifts.

Fourth, align product development to procedural trends by targeting cordless and low-profile solutions for minimally invasive and robotic-assisted workflows, while ensuring that reamers and saws meet the durability expectations of orthopedic and spinal applications. Fifth, deploy a regional commercial playbook that adapts pricing, regulatory strategy, and service delivery to the unique characteristics of provider segments in the Americas, Europe Middle East & Africa, and Asia-Pacific. Finally, invest in evidence generation through targeted clinical studies that demonstrate procedural efficiency, patient outcomes, and cost-effectiveness, thereby accelerating adoption among influential surgical centers and systems.

Comprehensive mixed-methods approach explaining primary clinician and procurement interviews, secondary regulatory and technical validation, and rigorous triangulation processes

The research underpinning this analysis combined structured primary engagements with domain experts, clinicians, procurement leaders, and supply chain specialists with rigorous secondary research and methodological triangulation to ensure reliability and practical relevance. Primary research included in-depth interviews with practicing surgeons across relevant specialties, procurement officers from public and private hospitals, and senior executives from manufacturing and distribution organizations to capture real-world decision criteria, pain points, and emerging priorities.

Secondary inputs were drawn from regulatory announcements, peer-reviewed clinical literature, technical specifications, trade and customs documentation, and public company filings to validate product-level characteristics, technological trends, and procedural adoption patterns. Data synthesis applied a cross-validation approach, reconciling qualitative insights from expert interviews with documented technical and regulatory evidence to minimize bias and enhance explanatory power.

The segmentation framework was validated through iterative stakeholder workshops and supplemented by supply chain mapping that identified critical nodes and potential single-origin vulnerabilities. Quality assurance processes included source triangulation, peer review by independent clinical advisors, and scenario testing to assess the robustness of strategic implications under differing operational conditions. This mixed-methods approach ensured that conclusions are grounded in both clinical practice and operational realities.

Synthesis of core findings that connects clinical adoption drivers, supply chain resilience, and strategic imperatives into an executive-level plan for action

In conclusion, the powered surgical instruments sector stands at an inflection point where technological innovation, procedural evolution, and supply chain realignment collectively determine competitive trajectories. Stakeholders that invest in resilient sourcing, modular product design, and outcome-focused service models will be best positioned to capture clinical adoption and sustain long-term partnerships with providers. The interplay between tariffs, regional policy shifts, and the accelerating adoption of minimally invasive and robotic-assisted procedures underscores the need for adaptive commercial strategies that prioritize evidence generation and operational reliability.

Manufacturers and distributors must act decisively to align R&D, manufacturing, and commercial approaches with emergent clinical workflows and procurement realities. Providers will benefit from engaging with suppliers that offer comprehensive lifecycle support and transparent total cost considerations. By synthesizing clinical needs, regulatory constraints, and supply chain imperatives into a coherent strategy, organizations can reduce exposure to external shocks and capitalize on the growing demand for precision, efficiency, and integrated instrument solutions. This executive summary provides a foundation for targeted actions that convert insight into measurable operational and clinical gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms into powered surgical tools for real-time decision support and precision
  • 5.2. Rise of single-use disposable powered surgical instruments driven by infection control concerns and regulatory pressure
  • 5.3. Development of cordless battery-powered surgical devices enabling greater OR mobility and streamlined instrument handling
  • 5.4. Adoption of advanced ergonomic designs in powered surgical equipment to reduce surgeon fatigue and improve procedural efficiency
  • 5.5. Connectivity of powered surgical instruments with hospital information systems and IoT platforms for workflow optimization and data analytics
  • 5.6. Advancements in energy-based sealing and cutting technologies integrated into powered instruments for multifunctional surgical applications
  • 5.7. Customization of powered surgical tools using 3D printing and modular components to meet patient-specific procedural requirements

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Powered Surgical Instruments Market, by Product Type

  • 8.1. Surgical Drill
    • 8.1.1. Corded Drill
    • 8.1.2. Cordless Drill
  • 8.2. Surgical Reamer
    • 8.2.1. Standard Reamer
    • 8.2.2. Threaded Reamer
  • 8.3. Surgical Saw
    • 8.3.1. Oscillating Saw
    • 8.3.2. Reciprocating Saw

9. Powered Surgical Instruments Market, by Power Source

  • 9.1. Electric
  • 9.2. Pneumatic

10. Powered Surgical Instruments Market, by Procedure Type

  • 10.1. Minimally Invasive
    • 10.1.1. Laparoscopic
    • 10.1.2. Robotic Assisted
  • 10.2. Open Surgery

11. Powered Surgical Instruments Market, by Application

  • 11.1. Dental Surgery
    • 11.1.1. Endodontics
    • 11.1.2. Implantology
  • 11.2. ENT
    • 11.2.1. Ear Surgery
    • 11.2.2. Sinus Surgery
  • 11.3. Maxillofacial Surgery
  • 11.4. Neurosurgery
    • 11.4.1. Cranial Surgery
    • 11.4.2. Spinal Surgery
  • 11.5. Orthopedic Surgery
    • 11.5.1. Fracture Fixation
    • 11.5.2. Joint Replacement
    • 11.5.3. Spine Surgery

12. Powered Surgical Instruments Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Specialty Clinics

13. Powered Surgical Instruments Market, by Distribution Channel

  • 13.1. Direct Sales
    • 13.1.1. Online Direct
    • 13.1.2. Sales Force
  • 13.2. Distributors
    • 13.2.1. National Distributors
    • 13.2.2. Regional Distributors
  • 13.3. Online Channels

14. Powered Surgical Instruments Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Powered Surgical Instruments Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Powered Surgical Instruments Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Stryker Corporation
    • 17.3.2. Medtronic plc
    • 17.3.3. Johnson & Johnson
    • 17.3.4. Zimmer Biomet Holdings, Inc.
    • 17.3.5. Smith & Nephew plc
    • 17.3.6. B. Braun Melsungen AG
    • 17.3.7. ConMed Corporation
    • 17.3.8. Olympus Corporation
    • 17.3.9. Integra LifeSciences Holdings Corporation
    • 17.3.10. MicroAire Surgical Instruments LLC
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제